Indegene Limited has informed the Exchange regarding allotment of 52951 securities pursuant to ESOP/ESPS at its meeting held on April 29, 2026
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Indegene Limited reported Q4 FY2026 consolidated revenue of Rs 10,034 million and full-year revenue of Rs 35,105 million, with annual profit of Rs 4,011 million. The Board recommended a final dividend of Rs 2.25 per equity share (face value Rs 2 each), subject to shareholder approval at the AGM. The company approved allotment of 52,951 securities under ESOP Scheme 2020 and RSU Scheme 2020. During the year, Indegene completed four acquisitions: BioPharm Parent Holdings Inc. (Rs 8,821 million), MJL Communications Group Ltd, Warn & Co Limited, and Cake Kommunikations Holdings GmbH. The auditors gave an unmodified opinion on the financial statements. An exceptional item of Rs 203 million was recognized for a proposed settlement of a US litigation matter related to TCPA violations.
Positive signals include strong revenue growth (up 23.7% YoY), dividend declaration, and successful acquisitions expanding global footprint. The TCPA litigation provision and transfer pricing contingent liability of Rs 1,114 million are headwinds to monitor.